Compare Morgan Stanley (MS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs BIO-TECHNE Corp — how do they compare? Morgan Stanley trades at $215.46 (market cap $331.60B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Morgan Stanley is far larger — about 29.7× BIO-TECHNE Corp's market cap, and Morgan Stanley pays the higher dividend (2.18%). Which is the better fit depends on your goals.
| MS | TECH | |
|---|---|---|
Market Cap | $331.60B | $11.16B |
Sector | Financials | Health |
52-Week High | $228.42 | $72.12 |
52-Week Low | $139.09 | $43.31 |
Dividend Yield | 2.18% | 0.45% |
Enterprise Value | — | $11.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $215.48, down 1.33% on the day, with a bullish technical signal and strong fundamental performance. Revenue grew to $66.0B in 2025, with net income reaching $16.9B and a profit margin of 25.6%. The stock has beaten earnings estimates for three consecutive quarters, and analysts maintain a consensus buy rating with a $241.36 price target. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook for MS is positive, driven by earnings momentum and strategic initiatives like AI adoption and high-profile IPOs. Risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers potential upside to the consensus target, but investors should monitor execution on growth initiatives and macroeconomic impacts on financial services.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
